Results 91 to 100 of about 258,109 (297)

Development and validation of a prediction model for primary non-response to IL-17A inhibitors in psoriasis

Frontiers in Medicine
BackgroundInterleukin-17A (IL-17A) inhibitors have revolutionized the treatment of moderate-to-severe plaque psoriasis, but a substantial proportion of patients experience primary non-response during the early treatment phase.ObjectivesTo identify ...
Qian Yu, Qian Yu, Yuxiong Jiang, Yuxiong Jiang, Yifan Hu, Yifan Hu, Min Dai, Min Dai, Siqi Li, Siqi Li, Jiangluyi Cai, Jiangluyi Cai, Nan Yang, Nan Yang, Yuanwenke Zhang, Yuanwenke Zhang, Yuemeng Huang, Yuemeng Huang, Chunyuan Guo, Chunyuan Guo, Yuling Shi, Yuling Shi, Jiajing Lu, Jiajing Lu   +23 more
doaj   +1 more source

Secukinumab sustains improvement in signs and symptoms of psoriatic arthritis: 2 year results from the phase 3 FUTURE 2 study [PDF]

, 2017
Objectives. To assess long-term efficacy, safety and tolerability of secukinumab up to 104 weeks in patients with active PsA. Methods. Patients with PsA (n = 397) were randomized to s.c. secukinumab 300, 150 or 75 mg or placebo at baseline, weeks 1, 2,
Delicha, Eumorphia-Maria, Gottlieb, Alice B., Kajekar, Radhika, Kirkham, Bruce, McInnes, Iain B., Mease, Philip J., Mpofu, Shephard, Pricop, Luminita, Rahman, Proton, Ritchlin, Christopher T.   +9 more
core   +2 more sources

Functional Impact of Structural Damage in Psoriatic Arthritis: Insights from a Prospective Cohort Study

Arthritis &Rheumatology, EarlyView.
Objective To examine the association between radiographic structural damage and physical function (PF) in psoriatic arthritis (PsA). Methods Data were analyzed from a large longitudinal PsA cohort. PF was measured using the Health Assessment Questionnaire (HAQ, 0–3) and Short Form‐36 PF subscale (SF‐36, 0–100); radiographic joint damage was measured ...
Pankti Mehta, Shangyi Gao, Virginia Carrizo Abarza, Fadi Kharouf, Daniel Pereira, Richard J. Cook, Dafna D. Gladman, Vinod Chandran, Denis Poddubnyy   +8 more
wiley   +1 more source

Tofacitinib in the management of active psoriatic arthritis: patient selection and perspectives. [PDF]

, 2019
Tofacitinib is an oral Janus kinase inhibitor approved for the treatment of psoriatic arthritis (PsA). It provides an alternative option for patients who have had an inadequate response and tolerance to other disease modifying antirheumatic drugs (DMARDs)
Beck, Kristen M, Liao, Wilson, Ly, Karen, Orbai, Ana-Maria, Smith, Mary P   +4 more
core  

Bioavailability, Antipsoriatic Efficacy and Tolerability of a New Light Cream with Mometasone Furoate 0.1% [PDF]

, 2012
Mometasone furoate, a potent glucocorticoid (class III) with a favorable benefit/risk ratio, has emerged as a standard medication for the treatment of inflammatory skin disorders.
Ayres JW, Borelli C, Brown PH, C. Schöllmann, C. Willers, Cornell RC, Dumas KJ, Faergemann J, H.C. Korting, Haigh JM, Hoffmann K, Hughes J, Katz HI, Kerscher MJ, Kirkland R, Koivukangas V, Korting HC, Korting HC, Korting HC, Korting HC, Kulhalli P, Medansky RS, Olsen EA, Poulsen J, Prakash A, Proksch E, Sequira J, Surber C, W. Wigger-Alberti, Wiedersberg S, Wilkinson SM   +30 more
core   +1 more source

Machine Learning to Predict Remission Between Six and 24 Months in Rheumatoid Arthritis: Insights from the JAK‐pot Collaboration

Arthritis &Rheumatology, Accepted Article.
Objective To develop, externally validate, and simplify a machine‐learning (ML) model to predict remission between six and 24 months in rheumatoid arthritis (RA) patients initiating TNF inhibitors, JAK inhibitors, IL‐6 inhibitors, abatacept, or rituximab, using data from 11 international registries in the JAK‐pot collaboration.
Zubeyir Salis, Denis Mongin, Denis Choquette, Louis Coupal, Catalin Codreanu, Florenzo Iannone, Roberto Caporali, Tore K Kvien, Sella Provan, Ruth Fritsch‐Stork, Dan Nordström, Nina Trokovic, Karel Pavelka, Jakub Závada, Ana Rodrigues, Ziga Rotar, Prodromos Sidiropoulos, Irini Flouri, Céline Lamacchia, Michele Iudici, Delphine Courvoisier, Kim Lauper, Axel Finckh   +22 more
wiley   +1 more source

Comparison between Intralesional Triamcinolone and Kligman's Formula in Treatment of Melasma

Acta Medica Iranica, 2016
Melasma is a common acquired skin disorder. While different treatments are currently being used, in many cases it is refractory to treatment. According to the effects of topical steroids in decreasing skin pigmentation, we studied the efficacy of this ...
Gholamreza Eshghi, leila khezrian, Fariba Esna Ashari   +2 more
doaj  

Epigenetic control of tissue resident memory T cells

Frontiers in Immunology
Tissue-resident memory T cells (TRM) represent a heterogeneous population of T cells that exhibit both effector and memory functionalities. They express specific gene signatures that enable them to occupy tissues without recirculating, thus providing a ...
Zhiyi Lan, Zhiyi Lan, Zhiyi Lan, Zeyu Chen, Zeyu Chen, Nan Yang, Nan Yang, Tong Liu, Tong Liu, Siqi Li, Siqi Li, Yuling Shi, Yuling Shi, Jun Gu, Jun Gu   +14 more
doaj   +1 more source

Acrodermatitis continua of Hallopeau: clinical perspectives. [PDF]

, 2019
Acrodermatitis continua of Hallopeau (ACH) is a rare, sterile pustular eruption of one or more digits. The condition presents with tender pustules and underlying erythema on the tip of a digit, more frequently arising on a finger than a toe.
Beck, Kristen M, Bhutani, Tina, Liao, Wilson, Ly, Karen, Smith, Mary Patricia, Thibodeaux, Quinn   +5 more
core  

Autoimmune conditions and comorbid depression in pregnancy: examining the risk of preterm birth and preeclampsia. [PDF]

, 2017
ObjectiveThe objective of this study was to determine whether prenatal depression interacts with autoimmune conditions to further increase the risk of preterm birth or preeclampsia.Study designOur sample included 3034 pregnant women with rheumatoid ...
Bandoli, G, Chambers, CD
core   +1 more source